Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
David Beidler, PhD
Researcher Senior Director, Precision Medicine, Early Clinical Development
Pfizer Inc.
Global Research and Development -
Rare Diseases Research Unit
1 Portland Street
Cambridge, Massachusetts, United States
As the Translational Sciences lead for the phosphodiesterase type 9 inhibitor project, Dr. Beidler contributed to the development, implementation, and analysis of pharmacodynamic biomarkers in the recent phase 1b study in stable sickle cell disease subjects. Dr. Beidler has over 17 years of pharmaceutical industry experience with biomarker/translational pharmacology strategy and clinical operations that span preclinical animal models, natural history/methodology studies, and early (Phase 1/2) clinical trials. Dr. Beidler has also served as the research project team leader and in vivo pharmacology lead on several pain/inflammation project teams that delivered multiple candidate compounds to the clinic.
Representative Publications:
Safety and Tolerability of PF-04447943 across a Clinical Trial Program Including 277 Patients
+myBinderRelated Content
-
Carolyn C. Hoppe, MDDr. Hoppe is a senior clinician and scie...
-
Gregory J. Kato, MDDr. Kato is a hematologist with an activ...
-
Sickle cell disease: Information for physicians and other health care professionalsSickle cell disease is a term for hemogl...
-
Sickle Cell Clinic at MLK JrThe outpatient sickle cell clinic at MLK...
-
Debunking the Myths About Sickle Cell Diseasehttps://www.youtube.com/watch?v=OZMwkE-W...
-
Integration of neuropsychology services in a sickle cell clinic and subsequent healthcare use for pain crisesObjective: Growing literature has docum...
-
Pfizer rare disease introduces Council for Change to further help SCD patientsFollowing a report earlier thi...
